Navigation Links
Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
Date:8/11/2008

onse to the drug combination, the body's response to the drug combination compared to chemotherapy alone and any evidence of anti-tumour activity.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

For more information about docetaxel (taxotere(R)) please visit http://www.taxotere.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. combination REOLYSIN(R)/paclitaxel and carboplatin clinical trial and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities comm
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... OriginOil Inc. (OTC/QB: OOIL), developer of Electro ... up large quantities of water, announced today that in ... the launch of the company's CLEAN-FRACâ„¢ industrial grade demonstrator ... STW Resources . , Immediately upon startup, the ... and achieved a 99.8% reduction in Turbidity on flowback ...
(Date:9/30/2014)... Boston, MA (PRWEB) September 30, 2014 ... Core Facility Management Benchmarking study which focuses on ... the common challenges core managers face today. , In ... were revealed. One of note is the year-over-year decrease ... contributions. Core managers appear to be feeling the constraints ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 ... and collaboration company is dedicated to supporting business ... needs. Julie Power, a carrier services ... ensure collaboration solutions stays connected and productive at ... the increased movement of businesses to cloud communications ...
(Date:9/30/2014)... Jersey (PRWEB) September 30, 2014 ... has been chosen by the Parenteral Drug Association ... 18 and 19, 2014) on container closure integrity testing. ... closure integrity test methods and philosophies detailed in the ... Integrity Evaluation. The course will span container ...
Breaking Biology Technology:OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 2iLab Solutions Announces the Results of the 2014 Core Facility Benchmarking Study 3SoundConnect Expands Carrier Services Division 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4
... 19 Abbott (NYSE:,ABT) will announce its 2008 third-quarter ... opens., The announcement will be followed by a ... Central time (9 a.m. Eastern), and will be,accessible through ... archived edition of the call will be,available after 11 ...
... China, Sept. 19 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC ... Chinese firm specializing in the manufacture,research, development, ... that at its 2008 Annual General Meeting ... the Company,s nominees to the,Board of Directors., ...
... Quarter 2008 Earnings Conference Call Tuesday, October 28, 2008, 5:00 ... p.m. U.S. EDT, FRAZER, Pa., Sept. ... quarter 2008 results for 5:00 p.m. EDT on Tuesday,October 28, 2008., ... October 28, 2008 Schedule, 4:10 p.m. EDT Q3 2008 results ...
Cached Biology Technology:China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders 2
(Date:9/30/2014)... Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich report that ... cells more sensitive to chemotherapeutic drugs. They have ... a new target for anti-tumor agents. , ... Professor Stephan Sieber of the Technische Universitt Mnchen ... a potential new weapon in the fight against ...
(Date:9/30/2014)... is available in German . ... behavioural response to risky situations such as exposure to ... now found in a long-term study on different populations ... metabolic rate and ambient temperature. High metabolic rates and ... in these scenarios birds were more likely to approach ...
(Date:9/30/2014)... 2014) People who suffer from asthma may think ... their asthma besides properly taking medications and avoiding allergic ... the Annals of Allergy, Asthma and Immunology , ... Asthma and Immunology (ACAAI), asthma sufferers can learn lessons ... woman described in the Annals article improved her asthma ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... study, scientists sampled the presence of 20 species of ... in the Adirondack Park. Calculating their occurrence at increasing ... are 36 percent more likely to occur near the ... that "human-sensitive" species were 26 percent less likely. Beyond ...
... of Nottingham has been used in a breakthrough study ... fully functioning fetal heart. The abdominal fetal ECG ... of Electrical and Electronic Engineering and on commercial sale ... company Monica Healthcare Ltd, has been used to observe ...
... to replace artificial preservatives in bread, making it tastier., ... mould fermented in sourdough bread, Michael Ganzle, professor and ... of Agricultural, Food and Nutritional Science and fellow researchers ... keep bread fresh without changing its flavour. Preservatives ...
Cached Biology News:WCS Adirondack Park study shows exurban residences impact bird communities up to 200 meters away 2WCS Adirondack Park study shows exurban residences impact bird communities up to 200 meters away 3Nottingham technology in heart development breakthrough 2Nottingham technology in heart development breakthrough 3Nottingham technology in heart development breakthrough 4
...
... Ribonuclease III (RNase III) from E. ... double-stranded RNA (dsRNA) to dsRNA fragments that ... dsRNA results in dsRNA fragments of 12-15 ... RNA composed of canonical ribonucleotides as well ...
...
Alexa Fluor 647 anti-mouse Qa-2...
Biology Products: